| Literature DB >> 26020620 |
Charles V Pollack1, Paul A Reilly, Richard Bernstein, Robert Dubiel, John Eikelboom, Stephan Glund, Menno V Huisman, Elaine Hylek, Chak-Wah Kam, Pieter W Kamphuisen, Joerg Kreuzer, Jerrold H Levy, Frank Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Jeffrey I Weitz.
Abstract
Idarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete reversal of the anticoagulation effect of dabigatran in animals and in healthy volunteers. The Study of the REVERSal Effects of Idarucizumab in Patients on Active Dabigatran (RE-VERSE AD™) is a global phase 3 prospective cohort study aimed at investigating idarucizumab in dabigatran-treated patients who present with uncontrollable or life-threatening bleeding, and in those requiring urgent surgery or intervention. We describe the rationale for, and design of the trial (clinicaltrials.gov NCT02104947).Entities:
Mesh：
Substances：
Year: 2015 PMID： 26020620 DOI： 10.1160/TH15-03-0192
Source DB: PubMed Journal: Thromb Haemost ISSN： 0340-6245 Impact factor: 5.249